NCT01916122
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Early Phase 1
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Patients with HER2+ or HR+ & HER2-negative breast cancer, must also have ER+ tumor(s)
Exclusions: 
https://ClinicalTrials.gov/show/NCT01916122